ArticleMikrochimica acta2025
Efficient colorimetric assay promotes the virtual screen of granzyme B inhibitors.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Granzyme B (GrmB) is a key biomarker for immune activation and tumor cell eradication, as well as the therapeutic target for autoimmune and chronic inflammatory disorders. Recent bioinformatic methods have been extensively applied to discover new sites of action, thereby enabling the screening of corresponding inhibitors. However, verification of silico predictions requires efficient experimental tests in vitro, and this work aims to provide an efficient assay method that enables the colorimetric detection of GrmB activity with high specificity and sensitivity (0.01 units) within a short time frame (30 min). With the design of a mirror peptide substrate that induces the aggregation of gold nanoparticle probes (AuNPs), a high-throughput color change can be quantified by a microplate reader. It has thus been applied to detect T-cell-secreted GrmB, as well as for inhibitor screening. Four candidate inhibitors have been screened out from a large-scale library pool containing 1.5 million small molecules. Combined with the computational simulation analysis, the Morgan fingerprints analysis, 2D binding mode analysis, etc. our study has further shown a shared interaction feature of the four inhibitors, indicating a new dominant inhibitory site of GrmB at Asn218. Therefore, this work provides a complementary tool for the virtual screening of GrmB inhibitors and reveals a new inhibitory site of GrmB. It may promote diagnostic and therapeutic applications of GrmB in immunotherapy and disease management.
Indexed as
Identifiers
40788416What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.